sever
member
ebolaviru
genu
marburgviru
genu
famili
filovirida
caus
sever
often
fatal
viral
hemorrhag
fever
human
nonhuman
primat
public
health
burden
filoviru
infect
remain
low
rel
public
health
threat
africa
outbreak
continu
affect
central
african
region
includ
recent
outbreak
uganda
democrat
republ
congo
high
case
fatal
rate
increas
public
health
threat
africa
biodefens
concern
associ
virus
result
consider
activ
filoviru
vaccin
develop
sever
vaccin
strategi
includ
dna
adenoviru
recombin
vesicular
stomat
viru
rvsv
viruslik
particl
vlp
recombin
parainfluenza
viru
vector
vaccin
develop
deliv
primarili
ebov
glycoprotein
gp
antigen
shown
confer
protect
anim
model
vaccin
strategi
shown
promis
result
protect
macaqu
concern
vaccin
safeti
preexist
vector
immun
manufactur
lack
commerci
interest
slow
progress
recent
investig
focus
identif
immun
paramet
might
serv
correl
protect
vaccin
nonhuman
primat
nhp
major
evid
suggest
igg
antibodi
level
import
protect
immun
macaqu
adenoviru
rvsvvector
ebov
gp
although
contribut
neutral
antibodi
protect
unclear
support
potenti
contribut
antibodi
protect
recent
provid
two
studi
demonstr
passiv
transfer
purifi
igg
nhp
survivor
sera
neutral
monoclon
antibodi
cocktail
could
confer
protect
ebola
marburg
viru
infect
addit
marzi
et
al
show
rvsv
mechan
protect
ebov
mediat
antibodi
ebovspecif
cellular
immun
respons
also
character
sever
immun
strategi
includ
dnaadenoviru
vlp
use
cell
deplet
experi
sullivan
et
al
recent
conclud
ebovspecif
cell
humor
immun
mediat
protect
ebov
infect
upon
adenovirusebovgp
immun
collect
studi
suggest
immun
paramet
correl
andor
confer
protect
may
multifactori
vari
vaccin
platform
howev
also
need
consid
like
differ
requir
induct
antiebov
immun
recal
respons
exposur
pathogen
like
longliv
immun
achiev
without
thelper
cell
case
gpspecif
antibodi
need
shown
maintain
time
helper
cell
requir
mount
fast
respons
infect
filoviru
vaccin
would
direct
use
human
risk
infect
africa
well
laboratori
worker
healthcar
provid
first
respond
soldier
travel
furthermor
ebov
vaccin
could
util
endang
wildlif
speci
gorilla
chimpanze
central
africa
risk
lethal
ebov
diseas
epidemiolog
studi
indic
ebov
outbreak
result
numer
death
anim
gabon
democrat
republ
congo
hinder
conserv
effort
protect
popul
vaccin
protect
risk
nhp
would
second
critic
benefit
human
ebov
zoonot
diseas
document
human
outbreak
aris
contact
diseas
nhp
prevent
diseas
anim
might
reduc
frequenc
ebov
transmiss
human
result
reduc
frequenc
outbreak
goal
identifi
vaccin
platform
ebov
filovirus
public
health
import
would
produc
promis
candid
use
human
endang
wildlif
speci
b
yield
multipl
vaccin
candid
increas
likelihood
optim
balanc
reactogen
immunogen
might
achiev
end
util
rabi
viru
rabv
vaccin
platform
develop
replicationcompet
b
replicationdefici
c
chemic
inactiv
vaccin
express
ebov
gp
strain
mayinga
rabv
still
consider
public
health
issu
africa
estim
death
report
yearli
bival
vaccin
confer
protect
rabv
ebov
would
econom
effici
public
health
tool
rabv
vaccin
platform
proven
excel
vaccin
vector
safe
induct
immun
hiv
sarscov
hepat
c
viru
attenu
rabvvector
vaccin
gener
delet
rabv
glycoprotein
g
gene
propag
virus
transcompl
cell
line
express
rabv
g
addit
betapropiolactonemedi
inactiv
rabvvector
vaccin
use
gener
kill
vaccin
candid
hepat
c
viru
bacillu
anthraci
optim
safeti
profil
primari
focu
develop
inactiv
vaccin
use
human
base
potenti
superior
safeti
success
histori
exist
beta
propiolactoneinactiv
rabv
vaccin
wide
use
human
howev
addit
develop
inactiv
rabvebov
vaccin
parent
recombin
rabv
vaccin
use
gener
rabvebov
vaccin
candid
deriv
sad
strain
use
wildlif
vaccin
bait
europ
suggest
addit
applic
vaccin
candid
therefor
live
attenu
rabvebov
vaccin
could
consid
use
africa
analog
campaign
protect
risk
nhp
lethal
ebov
infect
previou
research
rabvbas
vaccin
vector
express
antigen
indic
vaccin
highli
immunogen
nhp
rabvbas
vector
foreign
antigen
howev
replicationcompet
vaccin
vector
express
gagpol
env
analyz
nhp
immunogen
filoviru
antigen
express
rabv
vector
need
evalu
nhp
model
analyz
immunogen
three
differ
rabvebov
vaccin
vector
nhp
name
replicationcompet
replicationdefici
inactiv
virion
express
carri
ebov
gp
empti
replicationcompet
vector
serv
control
figur
outlin
immun
schedul
figur
four
group
rhesu
macaqu
immun
intramuscularli
im
caudal
thigh
muscl
follow
group
three
nhp
focusform
unit
ffu
black
group
four
nhp
ffu
red
group
four
nhp
ffu
blue
group
four
nhp
purifi
green
follow
immun
respons
vaccin
anim
time
vaccin
well
challeng
figur
notabl
goal
novel
vaccin
approach
develop
vaccin
protect
two
differ
highli
lethal
diseas
rabi
filoviru
induc
hemorrhag
fever
therefor
follow
rabv
ebov
gpspecif
immun
respons
shown
figur
three
vaccin
empti
control
vector
induc
seroconvers
rabv
g
earli
day
immun
increas
igg
level
day
slightli
decreas
level
sera
collect
day
contrast
day
ebov
gpspecif
humor
respons
detect
sera
anim
vaccin
replicationdefici
vaccin
figur
day
group
group
show
posit
signal
ebov
gpspecif
elisa
wherea
control
anim
group
background
signal
detect
figur
interestingli
replicationdefici
rabv
gdelet
vector
express
ebov
gp
induc
highest
ebov
gpspecif
respons
lowest
rabv
g
respons
like
due
fact
viru
encod
rabv
g
rabv
gspecif
immun
respons
result
g
protein
contain
initi
vaccin
particl
prepar
previou
research
live
rabvbas
vaccin
indic
preexist
antirabv
antibodi
prevent
success
secondari
immun
therefor
group
rhesu
macaqu
prime
inactiv
rabv
virion
contain
ebov
gp
receiv
boost
day
vaccin
figur
boost
increas
humor
respons
ebov
gp
well
rabv
g
group
significantli
figur
b
day
remark
even
anim
boost
show
increas
humor
respons
direct
rabv
g
ebov
gp
day
indic
vaccin
still
stimul
immun
system
high
elisa
titer
antirabv
g
antibodi
predict
protect
immun
host
still
want
confirm
humor
respons
rabv
viru
neutral
assay
vna
result
present
figur
indic
four
vaccin
induc
virusneutr
antibodi
earli
day
immun
notabl
vna
titer
well
critic
level
intern
unit
iu
consid
protect
rabv
infect
human
similar
total
igg
level
rabv
g
detect
increas
rabvspecif
immun
respons
vna
vaccin
group
contrast
rabv
unabl
detect
signific
level
virusneutr
antibodi
direct
ebov
group
compar
control
group
data
shown
also
analyz
cellular
respons
util
specif
elispot
larger
blood
sampl
collect
day
shown
tabl
anim
control
group
mount
cellular
respons
stimul
ebov
gpspecif
peptid
pool
highest
respons
detect
anim
immun
replicationcompet
vaccin
follow
replicationdefici
kill
viral
particl
day
howev
group
fail
detect
cellular
respons
one
two
anim
day
cellular
respons
detect
two
anim
previous
highest
respons
anim
show
background
level
ebov
gpspecif
cellular
respons
day
anim
transfer
niaid
facil
rocki
mountain
laboratori
ebov
challeng
sinc
challeng
viru
stock
never
util
rhesu
macaqu
infect
two
three
control
anim
day
pfu
ebov
strain
mayinga
prior
anim
ensur
pathogen
viru
stock
rapidli
develop
diseas
reach
hemorrhag
state
rash
day
post
challeng
respect
point
anim
euthan
accord
approv
protocol
base
find
infect
remain
anim
day
challeng
viru
stock
dose
challeng
experi
physic
exam
blood
draw
perform
day
postchalleng
outcom
ebov
challeng
clinic
find
present
figur
show
figur
anim
immun
live
replicationcompet
vaccin
group
surviv
challeng
expect
anim
control
group
nhp
human
euthan
accord
approv
protocol
mainli
base
high
viremia
day
figur
rash
two
four
anim
group
immun
replicationdefici
vaccin
two
four
anim
group
receiv
inactiv
rabvebov
particl
euthan
viral
load
detect
blood
anim
differ
three
control
anim
figur
interestingli
five
twelv
anim
control
challeng
viru
replic
undetect
viremia
wherea
three
anim
challeng
viru
detect
transient
one
group
two
time
point
group
figur
lack
protect
also
reflect
clinic
figur
anim
bodi
temperatur
averag
increas
within
first
day
challeng
return
origin
temperatur
near
day
post
challeng
figur
platelet
count
significantli
decreas
challeng
unprotect
anim
wherea
protect
anim
regain
normal
platelet
level
day
post
challeng
figur
serum
alanin
aminotransferas
alt
figur
serum
aspart
aminotransferas
ast
level
figur
monitor
liver
function
elev
level
seen
day
indic
liver
damag
result
ebov
infect
also
monitor
immun
respons
vaccin
anim
challeng
acut
convalesc
phase
diseas
shown
figur
three
anim
control
group
fail
mount
ebov
gpspecif
respons
cours
ebov
infect
contrast
three
group
vaccin
nhp
group
similar
level
antiebov
gp
antibodi
day
challeng
figur
challeng
day
ebov
gpspecif
antibodi
remain
level
day
challeng
figur
challeng
day
interestingli
rapid
increas
high
level
ebov
gpspecif
igg
observ
day
challeng
serum
five
anim
surviv
notabl
high
antibodi
level
detect
anim
detect
level
ebov
rna
blood
cours
challeng
three
anim
show
lower
signific
increas
ebov
gpspecif
antibodi
day
challeng
demonstr
transient
level
ebov
viremia
surviv
figur
lastli
fail
detect
increas
humor
respons
ebov
gp
serum
four
anim
day
post
challeng
anim
human
euthan
base
result
conclud
one
requir
success
rabvbas
ebov
vaccin
rapid
recal
respons
humor
immun
ebov
gp
ebov
challeng
result
present
also
indic
viru
specif
antibodi
import
control
ebov
infect
howev
antibodi
titer
ebov
gp
day
challeng
similar
three
group
importantli
within
group
two
anim
group
protect
two
therefor
decid
analyz
humor
immun
respons
greater
detail
first
perform
ebov
gp
specif
elisa
util
fulllength
ebov
gp
well
mucinlik
domain
mld
delet
version
ebov
mld
heavili
glycosyl
region
ebov
gp
ectodomain
previou
research
indic
antibodi
direct
mld
fail
neutral
ebov
even
enhanc
infect
result
shown
figur
demonstr
similar
humor
respons
detect
sera
anim
util
fulllength
ebov
gp
figur
ebov
figur
elisa
conclud
find
signific
differ
target
induc
antibodi
three
vaccin
least
regard
mld
seem
obviou
differ
ebov
gptarget
antibodi
within
differ
group
vaccin
analyz
qualit
differ
antibodi
depend
antibodi
nhp
shown
possess
better
antivir
properti
mediat
antibodydepend
cellular
cytotox
complement
activ
therefor
perform
isotypespecif
elisa
util
fulllength
ebov
gp
determin
differ
antibodi
isotyp
occur
vaccin
shown
figur
posit
control
nhp
ratio
day
postchalleng
around
wherea
ratio
averag
vaccin
anim
group
howev
six
day
challeng
ratio
chang
sera
collect
anim
group
group
four
anim
surviv
contrast
averag
ratio
group
group
group
two
anim
protect
data
suggest
humor
respons
might
benefici
control
ebov
infect
content
support
analysi
individu
anim
group
shown
figur
group
detect
ebov
rna
blood
day
also
highest
ratio
true
group
protect
anim
ratio
wherea
unprotect
anim
except
observ
one
protect
anim
group
clear
bia
toward
respons
indic
almost
howev
anim
low
antibodi
respons
even
day
challeng
figur
lastli
final
outcom
four
week
challeng
similar
surviv
anim
respons
ratio
similar
posit
control
gener
novel
find
strongli
indic
immun
respons
ebov
gp
advantag
protect
evalu
larger
anim
number
vaccin
approach
lastli
qualit
antibodi
differ
also
analyz
measur
avid
antibodi
challeng
vaccin
anim
group
shown
figur
day
avid
antibodi
serum
vaccin
anim
similar
group
control
anim
group
group
howev
avid
ebov
gpspecif
antibodi
significantli
increas
challeng
day
level
control
anim
vaccin
indic
rabvvector
induc
immun
respons
matur
long
period
time
howev
find
direct
correl
avid
ebov
gpspecif
antibodi
induc
vaccin
protect
diseas
two
addit
interest
find
worth
mention
list
seem
avid
ebov
gpspecif
immun
respons
complet
day
sinc
level
continu
increas
least
challeng
day
also
refer
day
last
time
point
analyz
challeng
ebov
strain
mayinga
secondli
even
interestingli
challeng
ebov
increas
avid
antibodi
direct
ebov
gp
see
figur
challeng
day
post
challeng
day
order
investig
antigenspecif
effect
analyz
avid
rabv
gspecif
antibodi
observ
similar
increas
avid
rabv
gspecif
antibodi
compar
ebov
gpspecif
antibodi
also
confirm
vna
supplement
figur
vna
show
signific
increas
surviv
anim
even
though
specul
mechan
protect
clear
increas
immun
respons
even
antigen
eg
rabv
g
express
challeng
viru
infect
previous
describ
gener
propag
safeti
immunogen
protect
efficaci
rabvebov
vaccin
candid
two
live
vaccin
candid
delet
entir
rabv
g
gene
found
avirul
upon
peripher
administr
mice
base
effici
incorpor
ebov
gp
virion
inactiv
vaccin
also
produc
treatment
rabvebov
vaccin
betapropiolacton
standard
method
util
current
human
rabv
vaccin
bival
vaccin
candid
induc
strong
humor
immun
rabv
g
ebov
gp
confer
protect
lethal
rabv
mouseadapt
ebov
challeng
mice
base
demonstr
promis
safeti
immunogen
protect
efficaci
live
inactiv
rabvebov
vaccin
mice
sought
evalu
vaccin
nonhuman
primat
three
vaccin
induc
clinic
sing
includ
fever
weight
loss
vaccin
abl
detect
vaccin
vector
blood
vaccin
nhp
rtpcr
data
shown
howev
safeti
studi
necessari
replicationcompet
vector
analyz
impact
ebov
gp
vaccin
immunogen
examin
follow
challeng
ebov
strain
mayinga
vaccin
candid
found
induc
potent
humor
immun
protect
lethal
challeng
result
indic
protect
immun
anim
larg
depend
induc
humor
immun
respons
ebov
gp
find
surpris
acut
viral
infect
often
control
antibodi
rather
cytotox
tcell
gener
import
control
chronic
infect
howev
previou
research
suggest
tcell
major
player
protect
ebov
infect
singl
vaccin
strategi
challeng
recent
studi
indic
gener
protect
nhp
differ
ebov
vaccin
seem
depend
presenc
antiebov
gp
antibodi
well
ebov
gpspecif
thelper
cell
moreov
exclud
tcell
play
role
viral
clearanc
memori
tcell
need
lastli
rel
high
background
elispot
assay
might
prevent
us
detect
low
cellular
respons
case
result
indic
major
role
ebov
gpspecif
antibodi
control
challeng
viru
replic
therefor
focus
respons
greater
detail
regard
find
nhp
group
protect
advantag
three
group
vaccin
nhp
similar
level
antiebov
gp
antibodi
analyz
use
ebov
gpspecif
elisa
suggest
qualit
differ
humor
respons
three
vaccin
first
investig
antiebov
gp
antibodi
direct
differ
region
within
glycoprotein
previou
work
other
indic
antibodi
direct
mld
within
ebov
gp
enhanc
infect
ebov
therefor
analyz
antiebov
gp
humor
respons
three
vaccin
util
fulllength
ebov
gp
ebov
howev
signific
differ
elisa
signal
serum
sampl
two
version
ebov
gp
conclud
mlddirect
antibodi
explain
differ
observ
protect
secondli
analyz
could
detect
differ
avid
antibodi
three
group
vaccine
differ
detect
surprisingli
found
avid
antiebov
gpspecif
antibodi
greatli
increas
challeng
similar
percentag
test
sera
wherea
explain
increas
antibodi
avid
transient
specif
antibodi
ebov
gp
avid
rabv
gspecif
antibodi
also
increas
well
establish
ebov
gpspecif
antibodi
induc
differ
ebov
vaccin
candid
may
weak
vna
activ
still
protect
find
indic
antibodydepend
cellmedi
cytotox
adcc
might
play
major
role
protect
ebov
infect
adcc
depend
antibodi
respons
analyz
total
igg
respons
also
igg
subtyp
respons
eg
result
indic
protect
anim
independ
group
ratio
wherea
unprotect
anim
higher
ratio
interestingli
two
anim
group
group
transient
highest
viral
load
also
ratio
fell
unprotect
protect
anim
result
clearli
indic
qualiti
antibodi
regard
isotyp
import
success
ebov
vaccin
base
ebov
gp
howev
protect
anim
group
also
highest
total
antibodi
level
therefor
conclud
case
rabiesbas
ebov
vaccin
high
level
gpspecif
antibodi
like
signific
shown
group
figur
summari
result
present
studi
clearli
indic
rabvbas
vector
induc
immun
respons
suffici
protect
lethal
ebov
infect
case
replicationcompet
rabv
vector
express
ebov
gp
improv
necessari
vector
could
use
protect
nhp
ebov
endem
set
note
would
best
establish
efficaci
via
oral
applic
alreadi
well
establish
live
rabv
wildlif
replicationdefici
inactiv
rabv
particl
protect
anim
therefor
respons
induc
vaccin
need
improv
resembl
respons
detect
replicationcompet
vaccin
protect
anim
case
replicationdefici
vector
viru
could
concentr
higher
titer
use
replic
compet
vaccin
use
immun
exclud
possibl
use
fivefold
lower
titer
immun
use
respons
differ
protect
moreov
anoth
vector
choic
could
matrix
protein
delet
replicationdefici
rabv
vector
express
ebov
gp
studi
vector
rabv
vaccin
indic
superior
even
compar
replicationcompet
rabv
case
inactiv
virion
contain
ebov
gp
new
construct
contain
exact
fusion
rabv
g
cytoplasm
domain
ebov
gp
increas
incorpor
level
twofold
previou
construct
contain
two
foreign
amino
acid
ebov
gp
transmembran
domain
rabv
g
cytoplasm
domain
show
better
respons
current
construct
mice
willet
schnell
unpublish
data
moreov
discov
glycosyl
pattern
ebov
gp
differ
rabv
particl
grown
bsr
cell
particl
grown
vero
cell
data
shown
therefor
believ
util
particl
contain
higher
level
ebov
gp
perhap
addit
immun
dose
would
bring
protect
rate
anim
reachabl
goal
safe
promis
dual
vaccin
studi
carri
strict
accord
recommend
describ
guid
care
use
laboratori
anim
nation
institut
health
offic
anim
welfar
unit
state
depart
agricultur
anim
work
approv
niaid
divis
intramur
research
anim
care
use
committe
iacuc
bethesda
md
protocol
rocki
mountain
laboratori
rml
protocol
facil
accredit
american
associ
accredit
laboratori
anim
care
procedur
carri
ketamin
anesthesia
train
personnel
supervis
veterinari
staff
effort
made
amelior
welfar
minim
anim
suffer
accord
weatheral
report
use
nonhuman
primat
recommend
anim
hous
adjoin
individu
primat
cage
allow
social
interact
control
condit
humid
temperatur
light
dark
cycl
food
water
avail
ad
libitum
anim
monitor
twice
daili
pre
postchalleng
fed
commerci
monkey
chow
treat
fruit
twice
daili
train
personnel
earli
endpoint
criteria
specifi
rml
iacuc
approv
score
paramet
use
determin
anim
human
euthan
fifteen
rabv
ebov
seroneg
rhesu
macaqu
assign
four
group
evalu
recent
develop
rabvebov
vaccin
candid
figur
group
four
anim
use
vaccin
candid
group
group
three
anim
serv
neg
control
day
group
control
anim
immun
intramuscularli
im
caudal
thigh
ffu
dose
live
parent
rabv
vaccin
group
anim
immun
im
ffu
dose
full
length
parent
rabv
vaccin
express
ebov
gp
design
group
anim
immun
im
dose
parent
vaccin
express
ebov
gp
contain
delet
rabi
glycoprotein
gene
design
group
anim
immun
im
betapropiolacton
inactiv
design
group
boost
inactiv
viru
day
macaqu
bled
day
transport
nation
institut
health
anim
center
poolesvil
md
nation
institut
health
rocki
mountain
laboratori
hamilton
mt
sinc
challeng
viru
stock
never
util
rhesu
macaqu
infect
two
three
control
anim
day
pfu
ebov
strain
mayinga
base
find
util
viru
virul
caus
ebov
hemorrhag
diseas
infect
remain
anim
day
challeng
viru
stock
dose
challeng
experi
physic
exam
blood
draw
perform
day
postchalleng
serum
aliquot
treat
gammairradi
per
approv
protocol
sent
thoma
jefferson
univers
analysi
enzymelink
immunosorb
assay
elisa
total
white
blood
cell
count
lymphocyt
platelet
reticulocyt
red
blood
cell
count
hemoglobin
hematocrit
valu
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
determin
edta
blood
hemavet
laserbas
hematolog
analyz
drew
scientif
waterburi
ct
serum
biochemistri
analyz
use
piccolo
xpress
chemistri
analyz
piccolo
gener
chemistri
panel
disc
abaxi
union
citi
ca
level
viral
rna
determin
use
quantit
rtpcr
qrtpcr
describ
previous
determin
viru
titer
nhp
blood
tissu
sampl
vero
cell
seed
plate
day
titrat
blood
sampl
thaw
serial
dilut
prepar
tissu
homogen
ml
plain
dmem
blood
serial
dilut
prepar
media
remov
cell
triplic
inocul
dilut
one
hour
dmem
supplement
fb
penicillinstreptomycin
lglutamin
ad
incub
cell
monitor
cytopath
effect
cpe
tissu
cultur
infecti
dose
calcul
sampl
employ
reed
muench
method
evalu
cell
respons
ebov
gp
nhp
pbmc
test
use
nhp
elispot
kit
r
system
cat
per
manufactur
instruct
briefli
micropl
fill
per
well
steril
cultur
media
fb
penstrep
block
media
incub
room
temperatur
nhp
pbmc
stimul
antigen
prepar
plate
antigen
prepar
steril
cultur
media
achiev
final
concentr
follow
gp
peptid
pool
jpt
pokewe
mitogen
posit
control
influenza
np
peptid
mimotop
neg
control
unstimul
cell
use
normal
spot
count
background
level
block
media
remov
antigen
ad
respect
pbmc
ad
respect
well
cellswel
plate
incub
h
cell
remov
plate
wash
four
time
wash
buffer
r
system
plate
stain
develop
accord
r
system
protocol
detect
antibodi
streptavidinap
bcipnbt
chromogen
plate
rins
deioniz
water
allow
dri
complet
scan
count
use
ctl
immunospot
reader
modifi
rapid
fluoresc
focu
inhibit
test
rffit
perform
determin
rabv
neutral
antibodi
level
immun
nhp
sera
threefold
serial
dilut
sera
standard
rabv
igg
cellgro
complet
serum
free
media
mediatech
incub
h
bnsp
parent
rabv
attenu
mutat
posit
concentr
achiev
moi
h
postinfect
neg
control
mixtur
ad
one
day
old
bsr
cell
deriv
cell
line
grown
dmem
mediatech
supplement
fb
atlanta
biolog
penicillinstreptomycin
mediatech
well
plate
plate
incub
h
plate
fix
aceton
stain
antirv
n
fujirebio
plate
read
percent
infect
cell
per
well
iu
antibodi
calcul
base
standard
infect
account
iu
neutral
antibodi
titer
determin
perform
focu
reduct
neutral
titrat
assay
frnt
describ
previous
briefli
vero
cell
seed
well
plate
gener
confluent
monolay
day
infect
serum
dilut
prepar
plain
dmem
incub
ffu
ebov
express
green
fluoresc
protein
ebovgfp
total
volum
min
media
remov
cell
serumviru
mixtur
ad
sampl
incub
min
mixtur
remov
cell
carboxymethyl
cellulos
mem
fb
ad
per
well
left
day
neutral
antibodi
titer
serum
sampl
consid
posit
dilut
show
reduct
frnt
gfpfoci
compar
control
without
serum
subconflu
flask
cell
human
kidney
cell
line
transfect
hemagglutinin
ha
tag
ebov
gp
express
plasmid
encod
amino
acid
ebov
gp
ectodomain
ebov
truncat
version
lack
amino
acid
ebov
gp
mucinlik
domain
ebov
plasmid
kindli
provid
erica
saphir
scripp
research
institut
la
jolla
ca
supernat
ad
equilibr
antiha
agaros
pierc
column
contain
ml
agaros
bed
volum
column
wash
bed
volum
tbst
tb
contain
tween
bed
volum
tb
ad
ml
ha
peptid
tb
pierc
ha
peptid
peptid
ad
flow
rate
incub
overnight
bound
ebov
gp
elut
ml
ha
peptid
tb
fraction
collect
analyz
ebov
gp
via
western
blot
nitrocellulos
membran
monoclon
antiha
antibodi
sigma
prepar
bsatbst
goat
antimous
igghrp
ebov
gp
posit
fraction
dialyz
mwco
dialysi
cassett
thermo
scientif
remov
excess
ha
peptid
use
elut
hatag
ebov
protein
rhesu
macaqu
sera
obtain
nih
test
analyz
humor
respons
ebov
gp
rabv
g
ebov
gp
antigen
coat
plate
obtain
harvest
supernat
transfect
cell
purifi
secret
protein
antiha
agaros
column
describ
plate
nunc
immulon
hbx
coat
overnight
ngwell
purifi
ebov
gp
ngwell
purifi
rabv
g
coat
buffer
plate
wash
three
time
pbst
pb
tween
block
room
temperatur
hour
dri
nonfat
milk
pbst
serum
sampl
dilut
bsapbst
ul
ad
well
serial
dilut
plate
incub
overnight
wash
three
time
pbst
incub
hour
ulwel
goat
antihuman
igghrp
plate
wash
pbst
develop
ulwel
sigmafast
ophenylenediamin
dihydrochlorid
opd
substrat
incub
minut
room
temperatur
reaction
stop
ul
absorb
read
nm
igg
subclass
specif
elisa
perform
ebov
gp
rabv
g
antihuman
abcam
antirhesu
nih
nhp
reagent
sourc
antibodi
plate
incub
opd
substrat
minut
stop
reaction
macaqu
sera
measur
total
igg
avid
rabv
g
ebov
gp
use
sodium
thiocyan
nascn
displac
elisa
determin
concentr
nascn
need
dissoci
antibodyantigen
interact
avid
assay
set
similar
elisa
protocol
describ
howev
sera
sampl
dilut
concentr
would
yield
od
read
nm
prior
incub
secondari
antibodi
plate
treat
increas
concentr
nascn
pb
minut
room
temperatur
well
receiv
nascn
incub
pb
plate
immedi
wash
three
time
pbst
tween
pb
continu
elisa
protocol
avid
assay
perform
triplic
data
analyz
prism
softwar
graphpad
version
statist
analysi
perform
use
unpair
ttest
welch
correct
compar
two
group
repres
twotail
pvalu
confid
interv
present
result
show
mean
measur
within
group
statist
follow
notat
use
indic
signific
two
group
p
p
p
